Reuters logo
BRIEF-Teva provides 2017 financial outlook
January 6, 2017 / 1:33 PM / a year ago

BRIEF-Teva provides 2017 financial outlook

Jan 6 (Reuters) - Teva Pharmaceutical Industries Ltd :

* Teva provides 2017 financial outlook

* Teva provides 2017 financial outlook

* Teva Pharmaceutical Industries Ltd - Copaxone 40 mg/ml is not expected to face generic competition in the United States during 2017

* Sees 2017 non gaap net revenues $23.8 billion - $24.5 billion

* Teva Pharmaceutical -- compared to 2016, foreign exchange rate fluctuations are expected to have an adverse impact of $0.8 billion on revenues in 2017

* Teva Pharmaceutical Industries Ltd sees 2017 non-gaap free cash flow $6.3 - $6.7 billion

* Teva Pharmaceutical Industries Ltd- expect generic revenues in united states to be approximately 43pct-45pct of generics segment revenues in 2017

* Sees 2017 adjusted eps $4.90 - $5.30

* Teva Pharma-entry of 2 AB-rated generic competitors in U.S. In February could reduce 2017 revenue by $1.0-$1.2 billion, reduce non-gaap EPS by $0.65 to $0.80

* FY 2017 earnings per share view $5.82, revenue view $25.32 billion -- Thomson Reuters I/B/E/S

* Teva Pharmaceutical Industries Ltd - expect profitability of generics segment in 2017 to be between 30pct and 31pct.

* Teva Pharmaceutical Industries Ltd - expect generic revenues in united states to be approximately 43 pct-45 pct of generics segment revenues in 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below